Patient-specific dendritic-cell vaccines for metastatic melanoma

RO Dillman, SR Selvan, PM Schiltz - New England Journal of …, 2006 - Mass Medical Soc
RO Dillman, SR Selvan, PM Schiltz
New England Journal of Medicine, 2006Mass Medical Soc
To the Editor: We are investigating the safety and efficacy of patient-specific vaccines
derived from short-term autologous tumor-cell lines in the treatment of melanoma. 1 In our
current trial, patients with distant metastatic or recurrent regional melanoma are candidates
for the receipt of an investigational vaccine consisting of autologous dendritic cells that have
been incubated with irradiated autologous tumor cells from a proliferating cell culture and
then suspended in granulocyte–macrophage colony-stimulating factor. The vaccine is …
To the Editor: We are investigating the safety and efficacy of patient-specific vaccines derived from short-term autologous tumor-cell lines in the treatment of melanoma.1 In our current trial, patients with distant metastatic or recurrent regional melanoma are candidates for the receipt of an investigational vaccine consisting of autologous dendritic cells that have been incubated with irradiated autologous tumor cells from a proliferating cell culture and then suspended in granulocyte–macrophage colony-stimulating factor. The vaccine is administered subcutaneously once a week for 3 weeks, then monthly for 5 months.2 Of the first 21 patients enrolled, 18 are alive a median of 3 . . .
The New England Journal Of Medicine